Akihiko Nagoshi

Kobe City Medical Center General Hospital

Papers

1

Total Citations

4

H-Index

1

About

Dr. Akihiko Nagoshi is a leading urologic oncologist whose research focuses on optimizing treatment strategies for high-risk and very high-risk prostate cancer, particularly through neoadjuvant chemohormonal therapy and robotic-assisted surgery. His most cited work investigates the critical role of dose compliance with estramustine phosphate when combined with degarelix acetate prior to robot-assisted radical prostatectomy. In a landmark study of 187 patients, Dr. Nagoshi demonstrated that adherence to this neoadjuvant regimen is a significant predictor of biochemical recurrence-free survival, offering a practical, patient-centered metric for improving outcomes in aggressive disease. This contribution provides clinicians with actionable insights for tailoring perioperative therapy. With his work accumulating citations and shaping protocols for very high-risk prostate cancer management, Dr. Nagoshi is recognized for bridging the gap between pharmacologic compliance and surgical oncology, advancing the precision of multimodal treatment in the robotic surgery era.

Research Focus

Key Achievements

1
H-Index
1
Papers
4
Total Citations
4
Avg Citations/Paper
🏆 Most Cited Paper
Dose compliance of estramustine phosphate in neoadjuvant chemohormonal therapy combined with degarelix acetate predicts the biochemical recurrence in patients with very high‐risk prostate cancer who underwent robot‐assisted radical prostatectomy
4 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 15
🏛 Institutions: Kobe City Medical Center General Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago